Novel evaluation of pulmonary hypertension associated with chronic lung disease using perfusion SPECT/CT: A pilot study.

perfusion imaging phosphodiesterase 5 inhibitors pulmonary hypertension single‐photon emission computed tomography/computed tomography vasodilator agents

Journal

Pulmonary circulation
ISSN: 2045-8932
Titre abrégé: Pulm Circ
Pays: United States
ID NLM: 101557243

Informations de publication

Date de publication:
Jul 2024
Historique:
received: 30 03 2024
revised: 26 06 2024
accepted: 19 07 2024
medline: 22 8 2024
pubmed: 22 8 2024
entrez: 22 8 2024
Statut: epublish

Résumé

In pulmonary hypertension (PH) associated with chronic lung disease (CLD), identifying patients who would benefit from pulmonary vasodilators is a significant clinical challenge because the presence of PH is associated with poorer survival. This study evaluated the severity of pulmonary circulation impairment in patients with CLD-PH using pulmonary perfusion single-photon emission computed tomography/computed tomography (SPECT/CT). This single-center, observational study enrolled patients with CLD-PH who had a mean pulmonary arterial pressure (PAP) ≥ 25 mmHg, as confirmed by right heart catheterization. The primary outcome was to measure the percentage of pulmonary perfusion defect (%PPD), calculated by dividing the perfusion defect volume from perfusion SPECT images by the lung volume from CT scan images. The secondary outcome was to assess the correlation between %PPD and baseline characteristics. The median %PPD was 52.4% (interquartile range, 42.5%-72.3%) in 22 patients. In multivariate linear regression analysis, both forced vital capacity (

Identifiants

pubmed: 39170759
doi: 10.1002/pul2.12423
pii: PUL212423
pmc: PMC11337537
doi:

Types de publication

Journal Article

Langues

eng

Pagination

e12423

Informations de copyright

© 2024 The Author(s). Pulmonary Circulation published by John Wiley & Sons Ltd on behalf of Pulmonary Vascular Research Institute.

Déclaration de conflit d'intérêts

Hiroshi Kimura worked in an endowment department supported by an unrestricted grant to Nippon Medical School from Actelion Pharmaceuticals Japan. The remaining authors declare no conflict of interest.

Auteurs

Kenichiro Atsumi (K)

Department of Pulmonary Medicine and Oncology, Graduate School of Medicine Nippon Medical School Tokyo Japan.
Department of Pulmonary Medicine and Medical Oncology, Nippon Medical School Tama Nagayama Hospital Tokyo Japan.

Yoshimitsu Fukushima (Y)

Department of Radiology Nippon Medical School Tokyo Japan.

Yosuke Tanaka (Y)

Department of Pulmonary Medicine and Oncology, Graduate School of Medicine Nippon Medical School Tokyo Japan.

Shunichi Nishima (S)

Department of Pulmonary Medicine and Oncology, Graduate School of Medicine Nippon Medical School Tokyo Japan.

Toru Tanaka (T)

Department of Pulmonary Medicine and Oncology, Graduate School of Medicine Nippon Medical School Tokyo Japan.

Masahiro Seike (M)

Department of Pulmonary Medicine and Oncology, Graduate School of Medicine Nippon Medical School Tokyo Japan.

Yoshiaki Kubota (Y)

Department of Cardiovascular Medicine Nippon Medical School Tokyo Japan.

Hiroshi Kimura (H)

Department of Pulmonary Medicine and Oncology, Graduate School of Medicine Nippon Medical School Tokyo Japan.
Department of Advanced Medicine for Pulmonary Circulation and Respiratory Failure, Graduate School of Medicine Nippon Medical School Tokyo Japan.
Respiratory Diseases Center, Fukujuji Hospital Japan Anti-Tuberculosis Association Tokyo Japan.

Classifications MeSH